Gilteritinib
8 abstracts
Abstract
Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia.Org: Massachusetts General Hospital, Harvard Medical School, Oryzon Genomics, Cornella De Llobregat, Barcelona Clinic Liver Cancer,
Abstract
Disparities in uptake of novel therapies for acute myeloid leukemia.Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Dana-Farber Cancer Institute,
Abstract
Gilteritinib plus azacitidine and venetoclax for FLT3-ITD mutated relapsed/refractory acute myeloid leukemia.Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, First Affiliated Hospital of Wannan Medical College, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, Shulan (Hangzhou) Hospital, Zhejiang Shuren University Shulan International Medical College,
Abstract
Gilteritinib or venetoclax in relapsed or refractory FLT3mut acute myeloid leukemia.Org: VCU School of Medicine, VCU Massey Cancer Center, VCU Department of Internal Medicine, VCU Department of Biostatistics,